Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press57310.17650/2686-9594-2022-12-4-52-59LITERATURE REVIEWОБЗОР ЛИТЕРАТУРЫPerioperative chemotherapy in the treatment of locally advanced forms of colon cancer: literature reviewПериоперационная химиотерапия в лечении местно-распространенных форм рака ободочной кишки: обзор литературыhttps://orcid.org/0000-0002-0522-0681ShabuninA. V.ШабунинА. В.
Russian Federation

125284, Moscow, 2nd Botkinskiy Proezd, 5

125284 Москва, 2-й Боткинский проезд, 5

https://orcid.org/0000-0001-8391-1210GrekovD. N.ГрековД. Н.
Russian Federation

125284, Moscow, 2nd Botkinskiy Proezd, 5

125284 Москва, 2-й Боткинский проезд, 5

https://orcid.org/0000-0001-5699-3695BagateliyaZ. A.БагателияЗ. А.
Russian Federation

125284, Moscow, 2nd Botkinskiy Proezd, 5

125284 Москва, 2-й Боткинский проезд, 5

https://orcid.org/0000-0003-0677-2338KulushevV. M.КулушевВ. М.
Russian Federation

 Vadim Maratovich Kulushev

125284, Moscow, 2nd Botkinskiy Proezd, 5

Вадим Маратович Кулушев

125284 Москва, 2-й Боткинский проезд, 5

kulushev@gmail.comSokolovN. Yu.СоколовН. Ю.
Russian Federation

125284, Moscow, 2nd Botkinskiy Proezd, 5

125284 Москва, 2-й Боткинский проезд, 5

MinenkovaA. G.МиненковаА. Г.
Russian Federation

119991, Moscow, 8 Trubetskaya St., Build. 2

119991 Москва, ул. Трубецкая, 8, стр. 2

https://orcid.org/0000-0001-5366-1281LebedevS. S.ЛебедевС. С.
Russian Federation

125284, Moscow, 2nd Botkinskiy Proezd, 5

125284 Москва, 2-й Боткинский проезд, 5

https://orcid.org/0000-0002-9042-942XLebedkoM. S.ЛебедькоМ. С.
Russian Federation

125284, Moscow, 2nd Botkinskiy Proezd, 5

125284 Москва, 2-й Боткинский проезд, 5

S.P. Botkin City Clinical Hospital, Moscow Healthcare DepartmentГБУЗ г. Москвы «Городская клиническая больница им. С.П. Боткина Департамента здравоохранения г. Москвы»I.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России2012202212452592012202220122022Copyright ©; 2022, ABV-pressCopyright ©; 2022, АБВ-пресс2022ABV-pressАБВ-прессhttps://onco-surgery.info/jour/about/editorialPolicieshttps://onco-surgery.info/jour/article/view/573

Neoadjuvant systemic therapy is standard of care for many tumors, especially of gastrointestinal ones. Neoadjuvant therapy has many potential advantages, including tumor downstaging, early treatment of micrometastatic disease and possibility to evaluate tumor biology in order to personalize treatment. Currently, perioperative chemotherapy isn’t the standard of treatment of advanced colon cancer. Limitations to widespread use of systemic therapy have included inaccurate radiological staging, concerns about tumor progression and a lack of randomized data.

Неоадъювантная химиотерапия является стандартом лечения многих опухолей, в особенности желудочно-кишечного тракта. Данный подход имеет много потенциальных преимуществ, включая регресс опухоли, раннее начало лечения микрометастазов, а также возможность оценивать биологию опухоли, тем самым персонализируя подход к лечению. В настоящее время неоадъювантная химиотерапия не является стандартом лечения местно-распространенного рака ободочной кишки, что связано с неточностью предоперационного стадирования, возможностью прогрессирования опухоли, а также отсутствием достаточного количества рандомизированных клинических исследований.

colon cancerneoadjuvant chemotherapystagingрак ободочной кишкинеоадъювантная химиотерапиястадирование1. Cancer Tomorrow. Available at: http://globocan.iarc.fr.Cancer Tomorrow. Available at: http://globocan.iarc.fr.2. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2021. Malignant tumors in Russia in 2020 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow, 2021. (In Russ.)Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2021. Malignant tumors in Russia in 2020 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow, 2021. (In Russ.)3. Hashiguchi Y., Muro K., Saito Y. et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 2020;25(1):1–42. DOI:10.1007/s10147-019-01485-zHashiguchi Y., Muro K., Saito Y. et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 2020;25(1):1–42. DOI:10.1007/s10147-019-01485-z4. Amin M.B., Greene F.L., Edge S.B. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017;67(2):93–9. DOI:10.3322/caac.21388Amin M.B., Greene F.L., Edge S.B. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017;67(2):93–9. DOI:10.3322/caac.213885. Benson A.B., Venook A.P., Al-Hawary M.M. et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018;16(7):874–901. DOI:10.6004/jnccn.2018.0061Benson A.B., Venook A.P., Al-Hawary M.M. et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018;16(7):874–901. DOI:10.6004/jnccn.2018.00616. Glynne-Jones R., Wyrwicz L., Tiret E. et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl 4):iv263. DOI:10.1093/annonc/mdy161Glynne-Jones R., Wyrwicz L., Tiret E. et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl 4):iv263. DOI:10.1093/annonc/mdy1617. Bosset J.F., Collette L., Calais G. et al. Chemotherapy with preoperative radiotherapy in rectal cancer [published correction appears in N Engl J Med 2007;357(7):728]. N Engl J Med 2006;355(11):1114–23. DOI:10.1056/NEJMoa060829Bosset J.F., Collette L., Calais G. et al. Chemotherapy with preoperative radiotherapy in rectal cancer [published correction appears in N Engl J Med 2007;357(7):728]. N Engl J Med 2006;355(11):1114–23. DOI:10.1056/NEJMoa0608298. Gérard J.P., Conroy T., Bonnetain F. et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24(28):4620–5. DOI:10.1200/JCO.2006.06.7629Gérard J.P., Conroy T., Bonnetain F. et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24(28):4620–5. DOI:10.1200/JCO.2006.06.76299. Smith N.J., Bees N., Barbachano Y. et al. Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trials. Br J Cancer 2007;96(7):1030–6. DOI:10.1038/sj.bjc.6603646Smith N.J., Bees N., Barbachano Y. et al. Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trials. Br J Cancer 2007;96(7):1030–6. DOI:10.1038/sj.bjc.660364610. Dighe Sю, Swift Iю, Magill Lю et al. Accuracy of radiological staging in identifying high-risk colon cancer patients suitable for neoadjuvant chemotherapy: a multicentre experience. Colorectal Dis 2012;14(4):438–44. DOI:10.1111/j.1463-1318.2011.02638.xDighe Sю, Swift Iю, Magill Lю et al. Accuracy of radiological staging in identifying high-risk colon cancer patients suitable for neoadjuvant chemotherapy: a multicentre experience. Colorectal Dis 2012;14(4):438–44. DOI:10.1111/j.1463-1318.2011.02638.x11. Dehal A.N., Graff-Baker A.N., Vuong B. et al. Correlation between clinical and pathologic staging in colon cancer: implications for neoadjuvant treatment. J Gastrointest Surg 2018;22(10): 1764–71. DOI:10.1007/s11605-018-3777-yDehal A.N., Graff-Baker A.N., Vuong B. et al. Correlation between clinical and pathologic staging in colon cancer: implications for neoadjuvant treatment. J Gastrointest Surg 2018;22(10): 1764–71. DOI:10.1007/s11605-018-3777-y12. Park S.Y., Cho S.H., Lee M.A. et al. Diagnostic performance of MRI- versus MDCT-categorized T3cd/T4 for identifying high-risk stage II or stage III colon cancers: a pilot study. Abdom Radiol (NY) 2019;44(5):1675–85. DOI:10.1007/s00261-018-1822-7Park S.Y., Cho S.H., Lee M.A. et al. Diagnostic performance of MRI- versus MDCT-categorized T3cd/T4 for identifying high-risk stage II or stage III colon cancers: a pilot study. Abdom Radiol (NY) 2019;44(5):1675–85. DOI:10.1007/s00261-018-1822-713. Rollvén E., Holm T., Glimelius B. et al. Potentials of high resolution magnetic resonance imaging versus computed tomography for preoperative local staging of colon cancer. Acta Radiol 2013;54(7):722–30. DOI:10.1177/0284185113484018Rollvén E., Holm T., Glimelius B. et al. Potentials of high resolution magnetic resonance imaging versus computed tomography for preoperative local staging of colon cancer. Acta Radiol 2013;54(7):722–30. DOI:10.1177/028418511348401814. Nerad E., Lambregts D.M.J., Kersten E.L.J. et al. MRI for local staging of colon cancer: can MRI become the optimal staging modality for patients with colon cancer? Dis Colon Rectum 2017;60(4):385–92. DOI:10.1097/DCR.0000000000000794Nerad E., Lambregts D.M.J., Kersten E.L.J. et al. MRI for local staging of colon cancer: can MRI become the optimal staging modality for patients with colon cancer? Dis Colon Rectum 2017;60(4):385–92. DOI:10.1097/DCR.000000000000079415. Malmstrøm M.L., Gögenur I., Riis L.B. et al. Endoscopic ultrasonography and computed tomography scanning for preoperative staging of colonic cancer. Int J Colorectal Dis 2017;32(6):813–20. DOI:10.1007/s00384-017-2820-xMalmstrøm M.L., Gögenur I., Riis L.B. et al. Endoscopic ultrasonography and computed tomography scanning for preoperative staging of colonic cancer. Int J Colorectal Dis 2017;32(6):813–20. DOI:10.1007/s00384-017-2820-x16. Lehnert T., Methner M., Pollok A. et al. Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients. Ann Surg 2002;235(2):217–25. DOI:10.1097/00000658-200202000-00009Lehnert T., Methner M., Pollok A. et al. Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients. Ann Surg 2002;235(2):217–25. DOI:10.1097/00000658-200202000-0000917. López-Cano M., Mañas M.J., Hermosilla E., Espín E. Multivisceral resection for colon cancer: analysis of prognostic factors. Dig Surg 2010;27(3):238–45. DOI:10.1159/000276974López-Cano M., Mañas M.J., Hermosilla E., Espín E. Multivisceral resection for colon cancer: analysis of prognostic factors. Dig Surg 2010;27(3):238–45. DOI:10.1159/00027697418. Lee W.S., Lee W.Y., Chun H.K., Choi S.H. En bloc resection for right colon cancer directly invading duodenum or pancreatic head. Yonsei Med J 2009;50(6):803–6. DOI:10.3349/ymj.2009.50.6.803Lee W.S., Lee W.Y., Chun H.K., Choi S.H. En bloc resection for right colon cancer directly invading duodenum or pancreatic head. Yonsei Med J 2009;50(6):803–6. DOI:10.3349/ymj.2009.50.6.80319. Gebhardt C., Meyer W., Ruckriegel S., Meier U. Multivisceral resection of advanced colorectal carcinoma. Langenbecks Arch Surg 1999;384(2):194–9. DOI:10.1007/s004230050191Gebhardt C., Meyer W., Ruckriegel S., Meier U. Multivisceral resection of advanced colorectal carcinoma. Langenbecks Arch Surg 1999;384(2):194–9. DOI:10.1007/s00423005019120. Taylor W.E., Donohue J.H., Gunderson L.L. et al. The Mayo Clinic experience with multimodality treatment of locally advanced or recurrent colon cancer. Ann Surg Oncol 2002;9(2):177–85. DOI:10.1007/BF02557371Taylor W.E., Donohue J.H., Gunderson L.L. et al. The Mayo Clinic experience with multimodality treatment of locally advanced or recurrent colon cancer. Ann Surg Oncol 2002;9(2):177–85. DOI:10.1007/BF0255737121. Mukai T. Nagasaki T., Akiyoshi T. et al. Laparoscopic multivisceral resection for locally advanced colon cancer: a single-center analysis of short- and long-term outcomes. Surg Today 2020;50(9):1024–31. DOI:10.1007/s00595-020-01986-9Mukai T. Nagasaki T., Akiyoshi T. et al. Laparoscopic multivisceral resection for locally advanced colon cancer: a single-center analysis of short- and long-term outcomes. Surg Today 2020;50(9):1024–31. DOI:10.1007/s00595-020-01986-922. Arredondo J., Baixauli J., Pastor C. et al. Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery. Clin Transl Oncol 2017;19(3):379–85. DOI:10.1007/s12094-016-1539-4Arredondo J., Baixauli J., Pastor C. et al. Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery. Clin Transl Oncol 2017;19(3):379–85. DOI:10.1007/s12094-016-1539-423. Matsuyama J., Doki Y., Yasuda T. et al. The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery 2007;141(5):570–80. DOI:10.1016/j.surg.2006.11.007Matsuyama J., Doki Y., Yasuda T. et al. The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery 2007;141(5):570–80. DOI:10.1016/j.surg.2006.11.00724. Tanaka K., Shimada H., Miura M. et al. Metastatic tumor doubling time: most important prehepatectomy predictor of survival and nonrecurrence of hepatic colorectal cancer metastasis. World J Surg 2004;28(3):263–70. DOI:10.1007/s00268-003-7088-3Tanaka K., Shimada H., Miura M. et al. Metastatic tumor doubling time: most important prehepatectomy predictor of survival and nonrecurrence of hepatic colorectal cancer metastasis. World J Surg 2004;28(3):263–70. DOI:10.1007/s00268-003-7088-325. Finlay I.G., Meek D., Brunton F., McArdle C.S. Growth rate of hepatic metastases in colorectal carcinoma. Br J Surg 1988;75(7):641–4. DOI:10.1002/bjs.1800750707Finlay I.G., Meek D., Brunton F., McArdle C.S. Growth rate of hepatic metastases in colorectal carcinoma. Br J Surg 1988;75(7):641–4. DOI:10.1002/bjs.180075070726. Scheer M.G., Stollman T.H., Vogel W.V. et al. Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. J Nucl Med 2008;49(6):887–91. DOI:10.2967/jnumed.107.048371Scheer M.G., Stollman T.H., Vogel W.V. et al. Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. J Nucl Med 2008;49(6):887–91. DOI:10.2967/jnumed.107.04837127. Zeamari S., Roos E., Stewart F.A. Tumour seeding in peritoneal wound sites in relation to growth-factor expression in early granulation tissue. Eur J Cancer 2004;40(9):1431–40. DOI:10.1016/j.ejca.2004.01.035Zeamari S., Roos E., Stewart F.A. Tumour seeding in peritoneal wound sites in relation to growth-factor expression in early granulation tissue. Eur J Cancer 2004;40(9):1431–40. DOI:10.1016/j.ejca.2004.01.03528. Amri R., Bordeianou L.G., Sylla P., Berger D.L. Variations in metastasis site by primary location in colon cancer. J Gastrointest Surg 2015;19(8):1522–7. DOI:10.1007/s11605-015-2837-9Amri R., Bordeianou L.G., Sylla P., Berger D.L. Variations in metastasis site by primary location in colon cancer. J Gastrointest Surg 2015;19(8):1522–7. DOI:10.1007/s11605-015-2837-929. De Gooyer J.M., Verstegen M.G., Lam-Boer J. et al. Neoadjuvant chemotherapy for locally advanced t4 colon cancer: a nationwide propensity-score matched cohort analysis. Dig Surg 2020;37(4):292–01. DOI:10.1159/000503446De Gooyer J.M., Verstegen M.G., Lam-Boer J. et al. Neoadjuvant chemotherapy for locally advanced t4 colon cancer: a nationwide propensity-score matched cohort analysis. Dig Surg 2020;37(4):292–01. DOI:10.1159/00050344630. Hershman D.L., Shao T., Kushi L.H. et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011;126(2):529–37. DOI:10.1007/s10549-010-1132-4Hershman D.L., Shao T., Kushi L.H. et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011;126(2):529–37. DOI:10.1007/s10549-010-1132-431. Weinrich M., Bochow J., Kutsch A.L. et al. High compliance with guideline recommendations but low completion rates of adjuvant chemotherapy in resected pancreatic cancer: A cohort study. Ann Med Surg (Lond) 2018;32:32–7. DOI:10.1016/j.amsu.2018.06.004Weinrich M., Bochow J., Kutsch A.L. et al. High compliance with guideline recommendations but low completion rates of adjuvant chemotherapy in resected pancreatic cancer: A cohort study. Ann Med Surg (Lond) 2018;32:32–7. DOI:10.1016/j.amsu.2018.06.00432. Bayraktar U.D., Chen E., Bayraktar S. et al. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma? Cancer 2011;117(11):2364–70. DOI:10.1002/cncr.25720Bayraktar U.D., Chen E., Bayraktar S. et al. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma? Cancer 2011;117(11):2364–70. DOI:10.1002/cncr.2572033. Glimelius B., Dahl O., Cedermark B. et al. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group [published correction appears in Acta Oncol 2006;45(1):110]. Acta Oncol 2005;44(8):904–12. DOI:10.1080/02841860500355900Glimelius B., Dahl O., Cedermark B. et al. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group [published correction appears in Acta Oncol 2006;45(1):110]. Acta Oncol 2005;44(8):904–12. DOI:10.1080/0284186050035590034. Des Guetz G., Nicolas P., Perret G.Y. et al. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer 2010;46(6):1049–55. DOI:10.1016/j.ejca.2010.01.020Des Guetz G., Nicolas P., Perret G.Y. et al. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer 2010;46(6):1049–55. DOI:10.1016/j.ejca.2010.01.02035. Chalabi M., Fanchi L.F., Dijkstra K.K. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020;26(4):566–76. DOI:10.1038/s41591-020-0805-8Chalabi M., Fanchi L.F., Dijkstra K.K. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020;26(4):566–76. DOI:10.1038/s41591-020-0805-836. Dehal A., Graff-Baker A.N., Vuong B. et al. Neoadjuvant chemotherapy improves survival in patients with clinical t4b colon cancer. J Gastrointest Surg 2018;22(2):242–9. DOI:10.1007/s11605-017-3566-zDehal A., Graff-Baker A.N., Vuong B. et al. Neoadjuvant chemotherapy improves survival in patients with clinical t4b colon cancer. J Gastrointest Surg 2018;22(2):242–9. DOI:10.1007/s11605-017-3566-z37. Mentha G., Majno P.E., Andres A. et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006;93(7):872–8. DOI:10.1002/bjs.5346Mentha G., Majno P.E., Andres A. et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006;93(7):872–8. DOI:10.1002/bjs.534638. Adam R., Pascal G., Castaing D. et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240(6):1052–64. DOI:10.1097/01.sla.0000145964.08365.01Adam R., Pascal G., Castaing D. et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240(6):1052–64. DOI:10.1097/01.sla.0000145964.08365.0139. Petrelli F., Coinu A., Lonati V., Barni S. A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer. Int J Colorectal Dis 2015;30(4):447–57. DOI:10.1007/s00384-014-2082-9Petrelli F., Coinu A., Lonati V., Barni S. A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer. Int J Colorectal Dis 2015;30(4):447–57. DOI:10.1007/s00384-014-2082-940. Jakobsen A., Andersen F., Fischer A. et al. Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta Oncol 2015;54(10):1747–53. DOI:10.3109/0284186X.2015.1037007Jakobsen A., Andersen F., Fischer A. et al. Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta Oncol 2015;54(10):1747–53. DOI:10.3109/0284186X.2015.103700741. Ingraham A.M., Cohen M.E., Bilimoria K.Y. et al. Comparison of hospital performance in nonemergency versus emergency colorectal operations at 142 hospitals. J Am Coll Surg 2010;210(2):155–65. DOI:10.1016/j.jamcollsurg.2009.10.016Ingraham A.M., Cohen M.E., Bilimoria K.Y. et al. Comparison of hospital performance in nonemergency versus emergency colorectal operations at 142 hospitals. J Am Coll Surg 2010;210(2):155–65. DOI:10.1016/j.jamcollsurg.2009.10.01642. Zhou H., Song Y., Jiang J. et al. A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer. Chin J Cancer Res 2016;28(6):598–605. DOI:10.21147/j.issn.1000-9604.2016.06.06Zhou H., Song Y., Jiang J. et al. A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer. Chin J Cancer Res 2016;28(6):598–605. DOI:10.21147/j.issn.1000-9604.2016.06.0643. Liu F., Yang L., Wu Y. et al. CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial. Chin J Cancer Res 2016;28(6):589–97. DOI:10.21147/j.issn.1000-9604.2016.06.05Liu F., Yang L., Wu Y. et al. CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial. Chin J Cancer Res 2016;28(6):589–97. DOI:10.21147/j.issn.1000-9604.2016.06.0544. Seymour M.T., Morton D. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol 2019;37:3504.Seymour M.T., Morton D. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol 2019;37:3504.45. Salimath J., Jones M.W., Hunt D.L., Lane M.K. Comparison of return of bowel function and length of stay in patients undergoing laparoscopic versus open colectomy. JSLS 2007;11(1):72–5.Salimath J., Jones M.W., Hunt D.L., Lane M.K. Comparison of return of bowel function and length of stay in patients undergoing laparoscopic versus open colectomy. JSLS 2007;11(1):72–5.46. Kelly M., Sharp L., Dwane F. et al. Factors predicting hospital length-of-stay and readmission after colorectal resection: a population-based study of elective and emergency admissions. BMC Health Serv Res 2012;12:77. DOI:10.1186/1472-6963-12-77Kelly M., Sharp L., Dwane F. et al. Factors predicting hospital length-of-stay and readmission after colorectal resection: a population-based study of elective and emergency admissions. BMC Health Serv Res 2012;12:77. DOI:10.1186/1472-6963-12-7747. Miller T.E., Thacker J.K., White W.D. et al. Reduced length of hospital stay in colorectal surgery after implementation of an enhanced recovery protocol. Anesth Analg 2014;118(5):1052–61. DOI:10.1213/ANE.0000000000000206Miller T.E., Thacker J.K., White W.D. et al. Reduced length of hospital stay in colorectal surgery after implementation of an enhanced recovery protocol. Anesth Analg 2014;118(5):1052–61. DOI:10.1213/ANE.000000000000020648. Karoui M., Rullier A., Luciani A. et al. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 – ECKINOXE trial. BMC Cancer 2015;15:511. DOI:10.1186/s12885-015-1507-3Karoui M., Rullier A., Luciani A. et al. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 – ECKINOXE trial. BMC Cancer 2015;15:511. DOI:10.1186/s12885-015-1507-349. Krarup P.M., Jorgensen L.N., Andreasen A.H., Harling H. Danish Colorectal Cancer Group. A nationwide study on anastomotic leakage after colonic cancer surgery. Colorectal Dis 2012;14(10):e661–7. DOI:10.1111/j.1463-1318.2012.03079.xKrarup P.M., Jorgensen L.N., Andreasen A.H., Harling H. Danish Colorectal Cancer Group. A nationwide study on anastomotic leakage after colonic cancer surgery. Colorectal Dis 2012;14(10):e661–7. DOI:10.1111/j.1463-1318.2012.03079.x50. Ryan R., Gibbons D., Hyland J.M. et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005;47(2):141–6. DOI:10.1111/j.1365-2559.2005.02176.xRyan R., Gibbons D., Hyland J.M. et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005;47(2):141–6. DOI:10.1111/j.1365-2559.2005.02176.x51. Karoui M., Gallois C., Piessen G. et al. Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years’ follow-up results of the PRODIGE 22 phase II randomized multicentre trial. Colorectal Dis 2021;23(6):1357–69. DOI:10.1111/codi.15585Karoui M., Gallois C., Piessen G. et al. Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years’ follow-up results of the PRODIGE 22 phase II randomized multicentre trial. Colorectal Dis 2021;23(6):1357–69. DOI:10.1111/codi.1558552. Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol 2012;13(11):1152–60. DOI:10.1016/S1470-2045(12)70348-0Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol 2012;13(11):1152–60. DOI:10.1016/S1470-2045(12)70348-0